TICKERNERD
Menu
NOVTNOVTTechnology · Scientific & Technical Instruments

NOVT Stock Forecast: Novanta, Inc. Price Predictions for 2026-2027

Last close, 2 Oct 2026
$149
+4.01% on the day

The 3 Wall Street analysts covering Novanta, Inc. hold a median 12-month price target of $195 — +30.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 1 Oct 2026 — in the upper half.

Market cap
$5.4B
Ticker Nerd rank
60 / 100
Median analyst target
$195
Analysts covering
3
Revenue$265.8M+10.3% y/y
Operating income$30.6M
Net income$12.5M
Free cash flow$57.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.8%
1M
+3.3%
YTD
+25.5%
1Y
+44.6%
From 52W high
−11.5%
From 52W low
+50.5%
$99
$169
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NOVT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Novanta, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Oct 2026
60 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
99
Issuance
82
Momentum
69
Accruals
51
Quality
47
Growth
41
Value
29
Volatility
24
Size
22

Revisions (99): Analysts have, on balance, been raising their forecasts.

Volatility (24): The share price moves around a lot.

Size (22): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NOVT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NOVT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$120$140$160$180$200Jan 26Apr 26Jul 26Oct 26NOVTHigh $195Median $195Low $194

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $194Median $195High $195

The green dot is the last close — the median target sits +30.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 May 2026BairdMaintainsOutperform$144 → $173
30 Mar 2026BairdUpgradeOutperform—
11 Aug 2025BairdMaintainsNeutral—
3 Mar 2025BairdMaintainsNeutral—
6 Nov 2024BairdMaintainsNeutral—
7 Aug 2024BairdMaintainsNeutral—
11 May 2023BairdMaintainsNeutral—
11 May 2022William BlairUpgradeOutperform—
13 Nov 2020BerenbergInitiatesHold—
13 May 2020BairdMaintainsNeutral—
28 Feb 2019BairdMaintainsNeutral—
9 May 2018BairdDowngradeNeutral—
27 Feb 2018William BlairInitiatesOutperform—
8 Dec 2017BairdInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NOVT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NOVT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 2 Oct 2026, Novanta, Inc. returned +44.6% against +15.4% for the S&P 500, dividends included.

NOVT vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160Jan 26Apr 26Jul 26Oct 26NOVTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NOVT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.9%
Analysts raising
2
Analysts cutting
0
Fundamentals

Novanta, Inc. (NOVT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
90.6×

Cheaper than 8% of US stocks

Price / sales
5.2×

Cheaper than 24% of US stocks

Price / book
3.3×

Cheaper than 29% of US stocks

EV / EBITDA
27.3×

Cheaper than 10% of US stocks

Growth & margins
Revenue growth (YoY)
10.3%

Higher than 53% of US stocks

Earnings growth (YoY)
178.9%

Higher than 89% of US stocks

Gross margin
45.5%

Higher than 56% of US stocks

Operating margin
11.5%

Higher than 66% of US stocks

Net margin
6.0%

Higher than 62% of US stocks

Returns & dividend
Return on equity
5.1%

Higher than 54% of US stocks

Return on assets
4.1%

Higher than 71% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Novanta, Inc. (NOVT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Novanta, Inc. has a market value of $5.4B and an enterprise value of $4.9B.

  • Revenue in the twelve months to 30 June 2026: $1.0B. The latest quarter grew 10.3% year on year.

  • Net income over the same four quarters: $61.8M, a 6.0% net margin.

  • Diluted earnings per share, trailing twelve months: $1.56.

  • Free cash flow in the twelve months to 30 June 2026: $114.3M.

  • Novanta, Inc. spent $51.8M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 37.8M.

  • Trailing P/E: 90.6×; forward P/E: 32.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Novanta, Inc. employs 3,000 people — $343K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Oct 2026

Data provided by Twelve Data

Peers

NOVT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelScientific & Technical Instruments
CompanyMarket capTKN rank
NOVTNovanta, Inc.$5.4B
60
STSensata Technologies Holding Plc$6.2B
93
VNTVontier Corp.$4.5B
84
ESEESCO Technologies, Inc.$7.0B
86
ITRIItron, Inc.$3.8B
76
BMIBadger Meter, Inc.$3.7B
40
CGNXCognex Corp.$10.4B
86

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Novanta, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NOVT news & analysis

How to Build a Humanoid Body

ETF Trends · 16 Sept 2026neutral

ETF Trends continues its series on constructing a humanoid, following up on an earlier breakdown of the three key build areas and a prior look at companies behind the technologies for a humanoid's brain. This installment addresses the components and firms involved in building a humanoid body.

Why it matters — A NOVT watcher would care because humanoid-construction articles highlight the technologies and supply chains tied to robotics and precision component demand, areas relevant to Novanta.

Are Robots the New Normal? Bet on these ETFs to Invest in the Future

Zacks Investment Research · 4 Sept 2026neutral

A Zacks article reports that robotics is entering a new era as artificial intelligence fuels adoption of humanoid robots, highlighting four ETFs that offer diversified exposure to the sector's growth.

Why it matters — A NOVT watcher would care because the broader robotics and automation sector's growth trends outlined in the piece are directly relevant to the markets in which Novanta operates.

Novanta to Present at Baird Global Healthcare Conference on Tuesday, September 15, 2026

Business Wire · 28 Aug 2026neutral

Novanta announced that CFO Robert Buckley and COO of Medical Solutions John Lesica will present at the Baird Global Healthcare Conference on September 15, 2026, in New York.

Why it matters — A NOVT watcher would care because the company's leadership is gaining visibility with healthcare-focused investors at a major industry conference.

How to Build a Humanoid Brain

ETF Trends · 19 Aug 2026neutral

ETF Trends published an article titled "How to Build a Humanoid Brain," the latest installment in a series on constructing humanoid robots. Following a prior guide covering the three pillars of such a project — brain, body, and energy systems — the piece focuses specifically on the robot's brain.

Why it matters — A NOVT watcher would care because humanoid robot development represents a growth area where precision motion control, photonics, and automation components could see demand.

Recent Price Trend in Novanta (NOVT) is Your Friend, Here's Why

Zacks Investment Research · 18 Aug 2026positive

Zacks Investment Research reported that Novanta (NOVT) passed its "Recent Price Strength" screen, indicating the stock is well positioned to maintain its recent uptrend. The screening tool identifies stocks that have shown sustained upward price momentum.

Why it matters — A NOVT watcher would care because the stock's inclusion in a price-strength screen points to continued positive momentum that may hold interest for investors tracking the company.

FAQ

Frequently asked questions about NOVT stock

What is the NOVT stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Novanta, Inc. have a median 12-month price target of $195, with estimates ranging from $194 to $195. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NOVT stock a buy right now?

Of the 3 analysts covering Novanta, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Novanta, Inc. 60 out of 100 across roughly 4,600 US stocks as at 1 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NOVT?

As at 1 Oct 2026, Novanta, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (99 of 100).

Will NOVT stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +30.2% from the last close, and Ticker Nerd's factor model ranks Novanta, Inc. 60 out of 100 as at 1 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NOVT stock forecast for 2030?

No analyst covering Novanta, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NOVT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $194 to $195 over the next 12 months.

How has NOVT stock performed over the past year?

Novanta, Inc. returned +44.6% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Novanta, Inc. do?

Novanta Inc. is a global technology company that provides core solutions for medical and advanced industrial equipment manufacturers.

What is the latest news on NOVT?

The most recent item we track (ETF Trends, 16 Sept 2026): "How to Build a Humanoid Body". ETF Trends continues its series on constructing a humanoid, following up on an earlier breakdown of the three key build areas and a prior look at companies behind the technologies for a humanoid's brain. This installment addresses the components and firms involved in building a humanoid body.

Company

About Novanta, Inc.

Novanta Inc. is a global technology company that provides core solutions for medical and advanced industrial equipment manufacturers. Novanta designs and manufactures precision photonics, vision, and motion control components and subsystems used in applications such as laser processing, robotics, automation, metrology, and scientific instrumentation. The company also supplies medical technologies for surgical imaging, visualization, identification, and other clinical workflows, supporting original equipment manufacturers across healthcare and life science markets. Novanta operates through its Automation Enabling Technologies and Medical Solutions segments, serving customers in North America, Europe, and Asia Pacific. Headquartered in Bedford, Massachusetts, Novanta focuses on mission-critical technologies that help its customers build highly specialized systems requiring precision, reliability, and performance.

CEO Mr. Matthijs Glastra · 3,000 employees · United States · https://www.novanta.com